| Catalog No. | HC347036 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Fusion - [AXL (AXL receptor tyrosine kinase, ARK, JTK11, Tyro7, UFO)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | AXLLG, Growth arrest-specific protein 6, AXL receptor tyrosine kinase ligand, GAS6, GAS-6 |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q14393 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -1199°C. |
|---|
| Alternate Names | AVB-500,AVB-S6-500,Aravive-S6,MYD1Fc,Ruga-S6,CAS:2268717-61-7 |
|---|
| Background | Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
